Multiple Sclerosis and Related Disorders

Papers
(The median citation count of Multiple Sclerosis and Related Disorders is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)
ArticleCitations
Characteristics and predictors of sexual dysfunction in men with multiple sclerosis84
Preliminary race-ethnicity-based analyses of fall risk among people with multiple sclerosis76
The clinical and radiological features and prevalence of Neuro-Behçet's Disease: A retrospective cohort multicenter study in Saudi Arabia68
Functional electrical stimulation combined with voluntary cycling accentuates VO2 response in people with severe multiple sclerosis: A pilot study65
OCT-Angiography in AQP4-positive NMOSD: finding subclinical disease using a new tool65
Spatio-Temporal Gait Parameters to Distinguish Multiple Sclerosis Disability during Dual- Task Walk60
Clinical outcomes of partial sensory root rhizotomy on patients with recurrence of multiple sclerosing trigeminal neuralgia after percutaneous balloon compression59
Utilizing the ISway to Identify and Compare Balance Domain Deficits in People with Multiple Sclerosis57
Inform Interferon Beta Exposure in the 2nd and 3rd Trimester of Pregnancy: A Register-Based Drug Utilisation Study in Finland and Sweden49
The Effect of Seasonal Variation on Relapse Rate in Patients with Relapsing-Remitting Multiple Sclerosis in Saudi Arabia49
Challenges of MS Patients for Receiving Health Care Services47
Fingolimod, teriflunomide and cladribine for the treatment of multiple sclerosis in women of childbearing age: description of drug utilization and exposed pregnancies in Germany47
Extended B-cell depletion beyond 6-months in patients receiving ocrelizumab or rituximab for CNS demyelinating disease47
Effectiveness of BBIBP-CorV vaccine in preventing SARS-CoV2 infection and severe outcomes in people living with multiple sclerosis: A population-based study45
Effectiveness and safety of switching from fingolimod and natalizumab to rituximab in patients with relapsing remitting multiple sclerosis45
Effects of flexible scheduling and virtual visits on burnout for clinicians: 1- year follow-up44
How important are COVID-19 vaccine responses in patients with MS on disease-modifying therapies?44
Infrequent patterns in cerebrospinal fluid isofocusing test: Clinical significance and contribution of IgG index and Reiber diagram to their interpretation43
The presence of SARS-CoV2 antibodies in MS patients42
Nordic clues for uncovering the aetiology of Multiple Sclerosis41
Dosing schedules for Ofatumumab in multiple sclerosis: Overegging the pudding39
Quantitative and qualitative features of acute phase-adverse events following SARS-CoV-2 vaccination in a large sample of people with multiple sclerosis39
Risk factors associated with permanent disability in neuromyelitis optica spectrum disorders39
Infection incidence and management in multiple sclerosis patients after initiating disease-modifying therapy38
Antigen-specific tolerization in human autoimmunity: Inhibition of interferon-beta1a anti-drug antibodies in multiple sclerosis: A case report38
Outcomes of COVID-19 among patients treated with subcutaneous interferon beta-1a for multiple sclerosis38
Body size perceptions & diet modification in youth with multiple sclerosis37
Utilizing metabolomic profiling as a supportive diagnostic tool for radiologically isolated syndrome37
Efficacy and safety of disease-modifying therapies in pediatric-onset multiple sclerosis: A systematic review of clinical trials and observational studies36
Cerebrospinal fluid biomarkers as predictors of multiple sclerosis severity36
Does the use of the Bruton Tyrosine Kinase inhibitors and the c-kit inhibitor masitinib result in clinically significant outcomes among patients with various forms of multiple sclerosis?36
Spinal cord size as promising biomarker of disability outcomes after hematopoietic stem cell transplantation in multiple sclerosis35
Impact of resilience, social support, and personality traits in patients with neuroinflammatory diseases during the COVID-19 pandemic34
Advances in maintenance therapies for neuromyelitis optica spectrum disorders: A new era of targeted drugs34
Multiple sclerosis, neuromyelitis optica spectrum disorder and COVID-19: A pandemic year in Czechia33
Markedly elevated cerebrospinal fluid white blood cell count in multiple sclerosis: How high is too high?33
Cognitive reserve as a moderating factor between EDSS and cognition in multiple sclerosis33
Relationships between changes in daily occupations and health-related quality of life in persons with multiple sclerosis during the COVID-19 pandemic33
Five-year visual outcomes after optic neuritis in anti-MOG antibody-associated disease32
Social Cognitive Theory variables as correlates of physical activity in fatigued persons with multiple sclerosis32
Evaluation of mental performance and cognitive functions of children and adolescents diagnosed with radiologically isolated syndrome32
Longitudinal analysis of disability outcomes among young people with MS31
Economic Analysis for Introduction of Cladribine Tablets as a Treatment for Relapsing Multiple Sclerosis Patients with High Disease Activity in Kuwait30
Radiomics models based on cortical damages for identification of multiple sclerosis with cognitive impairment30
Test-retest reliability of the Swedish version of the Modified Fatigue Impact Scale in people with mild to moderate multiple sclerosis29
Symptoms of PTSD and depression in newly diagnosed people with multiple sclerosis during the outbreak Oct.7th war on Gaza: A case-control study from Jordan29
Biomarkers in patients with autoimmune optic neuritis not associated with multiple sclerosis: Demographic, clinical and prognostic features29
Real World Experience for Cladribine Tablets in Management of Relapsing Multiple Sclerosis in UAE: Cohort Study from Rashid Hospital -Dubai29
Glucagon-like peptide-1 agonist safety and efficacy in a multiple sclerosis cohort29
The nutritional risk in patients with neuromyelitis optica spectrum disorder29
CNS resilience in the progression of MS28
Incidence of multiple sclerosis relapses and pseudo-relapses following COVID-19 vaccination28
Investigation of the correlation between mildly deleterious mtDNA Variations and the clinical progression of multiple sclerosis28
Role of serostatus in pediatric neuromyelitis optica spectrum disorders: A nationwide multicentric study28
Diagnosis of multiple sclerosis using optical coherence tomography supported by artificial intelligence28
Depression and anxiety in MS: symptoms or comorbidity?27
Rabies vaccination and multiple sclerosis relapse: A retrospective cohort study27
Pediatric neuromyelitis optica spectrum disorders in Portugal: A multicentre retrospective study27
Italian translation and psychometric validation of the ABILHAND-26 and its correlation with upper limb objective and subjective measures in multiple sclerosis subjects27
Clinical impact of Ocrelizumab extended interval dosing during the COVID-19 pandemic and associations with CD19+ B-cell repopulation27
Discrimination of multiple sclerosis using scanning laser ophthalmoscopy images with autoencoder-based feature extraction27
The importance of the patient's perspective in decision-making in multiple sclerosis: Results of the OwnMS patient perspectives study26
Investigating the effects of 25-hydroxyvitamin D3 on clinical outcomes in multiple sclerosis patients: A randomized, double-blind clinical trial- a pilot study26
Self-reported cognitive function mediates the relationship between employment status and cognitive functioning in persons with multiple sclerosis26
Using myelin water imaging to link underlying pathology to clinical function in multiple sclerosis: A scoping review26
The outcome of a national MS-Covid-19 study: What the Turkish MS cohort reveals?26
The telephone-based application of the modified fatigue impact scale in individuals with multiple sclerosis: An investigation of measurement properties26
Analysis of Evusheld safety and efficacy in multiple sclerosis patients26
What are T-cells telling us about how EBV causes MS?26
The Indian multiple sclerosis and allied demyelinating disorders registry and research network (IMSRN): Inception to reality26
Clinical outcome analysis of patients with multiple sclerosis – Analysis from the UK Medical Cannabis Registry25
Do we still need OCBs in MS diagnosis and how many?25
COVID-19 vaccines and multiple sclerosis disease-modifying therapies25
Comparison of the effects of mechanical hippotherapy and Cawthorne-Cooksey exercises in patients with multiple sclerosis: Randomized trial25
Milk and multiple sclerosis: A possible link?25
Why I created the Rachel Horne Prize for Women's Research in Multiple Sclerosis25
Contribution of relapse-associated worsening to overall disability accrual in patients with relapsing-onset multiple sclerosis: A mediation analysis25
Managing cognitive impairment and its impact in multiple sclerosis: An Australian multidisciplinary perspective25
Real world study of ocrelizumab in multiple sclerosis: Kuwait experience24
Effects of backward walking training on balance, gait, and functional mobility in people with multiple sclerosis: A randomized controlled study24
Demographic features, behavioral measures, and clinical factors as predictors of cognitive function in patients with multiple sclerosis24
The relationship between bladder functions, pelvic floor muscle strength, fall, and fatigue in multiple sclerosis24
A multicenter study of radiologically isolated syndrome in children and adolescents: Can we predict the course?24
Evaluation of the use of high-efficacy treatments (HETs) in patients with relapsing-remitting multiple sclerosis in Argentina24
Post-vaccination SARS-Cov-2 T-cell receptor repertoires and multiple sclerosis and related disorders: Correspondence24
The Relationship Between Smoking and Multiple Sclerosis Severity in Saudi Arabia23
The effect of a mobile education application (MobilMS) developed for multiple sclerosis patients in Turkey on symptom management and quality of life: A randomized controlled study23
Multiple Sclerosis During Pregnancy: Data from the MS Clinic in Benghazi Medical Center23
Prolonged visual evoked potential latency predicts longitudinal worsening of fatigue in people with multiple sclerosis23
Clinical, Evolutionary and Etiological Particularities of Inflammatory Optic Neuropathies: An Algerian Population23
Evaluation of adherence to treatment in patients with multiple sclerosis from Latin America23
Independent and reproducible hippocampal radiomics biomarkers for multisite multiple sclerosis and neuromyelitis optica spectrum disorders23
Menopausal symptoms and hormone therapy in women with multiple sclerosis: A baseline-controlled study23
A mixture model for differentiating longitudinal courses of multiple sclerosis23
Vitamin D-Related Parameters and Th17 Pathway in Multiple Sclerosis: A Serological, Transcriptomic and Functional Study22
What is the role of diet for multiple sclerosis? Why epidemiological studies don't give the full answer22
Sexual Dysfunction during Multiple Sclerosis22
Primary Antiphospholipid Antibody Syndrome Mimicking a Progressive MS: Case Report22
Sexual Dysfunctions and Self-Esteem in Multiple Sclerosis: A Tunisian Study22
The dilated cortical veins found in multiple sclerosis can explain the reduction in glymphatic flow22
Leber Hereditary Optic Neuropathy Presenting as Bilateral Visual Loss and White Matter Disease22
Atypical Cerebral MRI Imaging Associated Related to NMOSD22
Neuromyelitis Optica Spectrum Disorders Mimicking Wernicke's Encephalopathy: Difficult Differential Diagnosis21
Real World Experience for Clad T in the Management of Relapsing Multiple Sclerosis in the United Arab Emirates21
Aims & Scope & Editorial Board21
Oral disease modifying therapies – A game changer for treatment decision in untreated patients with RRMS and CIS? – A swiss single center cross-sectional study21
Reliability and Validity of the Arabic Version of Brief International Cognitive Assessment for Multiple Sclerosis in Egyptian Pediatric Multiple Sclerosis Patient21
Effectiveness & Safety Profile of Fingolimod in Treating Omani Patients with Multiple Sclerosis, Single Tertiary Center Experience21
Real-world operation of multiple sclerosis centres in Central-Eastern European countries covering 107 million inhabitants21
Expert Opinion on Long-Term Use of Cladribine Tablets for Multiple Sclerosis: Systematic Literature Review of Real-World Evidence21
Identification of potential key genes and immune infiltration in Multiple sclerosis21
Real-Life Study with Cladribine: Kuwait Experience21
Health related quality of life and perceived social support in French and Lebanese MS patients: A comparative study21
The effects of bupropion on sexual dysfunction in female patients with multiple sclerosis: A double-blind randomized clinical trial21
Role of Type 1 Interferons therapy on Adverse Clinical Outcomes on COVID-19 in Hospitalized Multiple Sclerosis Patients20
The Use of Complementary Medicine for Patients with Multiple Sclerosis in Morocco20
Real-world data about the side effects of SARS-CoV-2 vaccinations can be obtained only from representative samples undergoing comprehensive investigations20
A one year follow of patients with multiple sclerosis during COVID-19 pandemic: A cross-sectional study in Qom province, Iran20
Tobacco Smoke and Sleep Quality Among People with Multiple Sclerosis: A Comparison Study20
The Use of Ocrelizumab in Pediatric Multiple Sclerosis Patients in the United Arab Emirates: A Retrospective Study20
Familial neuromyelitis optica spectrum disorders: Case series and systematic review20
RION Vs CRION: The Roadmap20
Reliability and Validity of the Arabic Version of Brief International Cognitive Assessment for Multiple Sclerosis in Egyptian Pediatric Multiple Sclerosis Patients20
Physical activity together for MS (PAT-MS): Secondary outcomes of a randomized controlled feasibility trial20
Epidemiological Parameters of Multiple Sclerosis in Chaharmahal- Bakhtiari Province, Iran19
Fatigue in Patients with Multiple Sclerosis in an Algeria Cohort19
Criterion validity of muscle strain analyses of skeletal muscle function in patients with multiple sclerosis19
Involvement Peripheral Nerve System in Multiple Sclerosis19
Switching to natalizumab or fingolimod in multiple sclerosis: Comparative effectiveness and effect of pre-switch disease activity19
Engagement in volunteering activities by persons with multiple sclerosis in Switzerland19
Multiple Sclerosis Patients’ Perception of Traditional and Complementary Medicine19
The Clinical Course of Multiple Sclerosis Patients in Oran19
Analysis of determinants of treatment change in adult paediatric-onset MS patients19
Clinical onset of CNS demyelinating disease after COVID-19 vaccination: denovo disease?19
Evaluation of the times of disability progression and related factors in patients with primary progressive multiple sclerosis from Argentina18
Real world comparison of teriflunomide and dimethyl fumarate in naïve relapsing multiple sclerosis patients: Evidence from the Italian MS register18
Risk factors for COVID-19 infection in patients with multiple sclerosis: a nested case–control study18
Comparative pharmacokinetics and bioavailability of monomethyl fumarate following a single oral dose of Bafiertam® (monomethyl fumarate) versus Vumerity® (diroximel fumarate)18
Digital biomarkers can highlight subtle clinical differences in radiologically isolated syndrome compared to healthy controls18
Can serum glial fibrillary acidic protein (GFAP) solve the longstanding problem of diagnosis and monitoring progressive multiple sclerosis18
Mind wandering in people with Multiple Sclerosis: A psychometric study18
A comprehensive assessment of patient experience and disease-related awareness in multiple sclerosis: A questionnaire-based nation-wide survey in Turkey18
The relationship between dysphagia, respiratory functions and anthropometry in patients with multiple sclerosis17
What telomeres teach us about MS17
Cognitive-motor interference in people with mild to moderate multiple sclerosis, in comparison with healthy controls17
The Multiple Sclerosis Intimacy and Sexuality Questionnaire (MSISQ): Validation of the Turkish version in patient with multiple sclerosis17
Claims-Based Relapse and Hospitalization Rates in Patients with Multiple Sclerosis Treated with Natalizumab or Ocrelizumab17
A variant of uncertain significance in SDHAF1, the succinate dehydrogenase chaperone protein, in an adult patient with spastic paraparesis and leukoencephalopathy17
Autoimmune encephalitis: A retrospective monocentric experience17
Monitoring of safety and effectiveness of cladribine in multiple sclerosis patients over 50 years17
Neutrophil to lymphocyte ratio may be a useful marker in distinguishing MOGAD and MS and platelet to lymphocyte ratio associated with MOGAD activity17
Electronic pill bottle monitoring versus reminders to promote medication adherence for people with multiple sclerosis: A randomized, virtual clinical trial17
Vitamin D3 Improves Behavioral Dysfunction and Promotes Remyelination in Multiple Sclerosis Model Induced by Cuprizone17
Plasma 24-hydroxycholesterol is associated with narrower common carotid artery and greater flow velocities in relapsing multiple sclerosis17
Missed MS or MIMS not prodromal MS: Expanding the diagnostic MS spectrum17
The metabolic potential of the paediatric-onset multiple sclerosis gut microbiome17
Autoimmune encephalitis associated with COVID-19: A systematic review17
Performance of highly cited multiple sclerosis publications in the Science Citation Index expanded: A scientometric analysis17
Baseline neurofilament levels in cerebrospinal fluid do not correlate with long-term prognosis in multiple sclerosis17
Expert Opinion on COVID-19 Vaccination and the Use of Cladribine Tablets17
Is breastfeeding in MS harmful or not? An answer from real-world Czech data17
The Adherence and Clinical Outcomes in Patients with Relapsing Multiple Sclerosis Treated with Subcutaneous Interferon Beta-1A: Results from the Main-MS Study16
Long-Term Efficacy for Patients Receiving Cladribine Tablets in CLARITY/CLARITY Extension: Primary Results from 9–15 Years of Follow-Up in the CLASSIC-MS Study16
Relationship between cognitive disturbances and sleep disorders in multiple sclerosis is modulated by psychiatric symptoms16
Humoral response to Epstein-Barr virus in patients with multiple sclerosis treated with B cell depletion therapy16
SARS-CoV-2 infection increases long-term multiple sclerosis disease activity and all-cause mortality in an underserved inner-city population16
Validity of the 30-Second Sit-to-Stand test as a measure of lower extremity function in persons with multiple sclerosis: Preliminary evidence16
The role of oligoclonal band count and IgG index in treatment response and disease activity in multiple sclerosis16
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD) in Chile: lessons learned from challenging cases16
A patient with concurrent multiple sclerosis and moyamoya disease16
Longitudinal assessment of cervical spinal cord compartments in multiple sclerosis16
Risk of disease relapse following COVID-19 vaccination in patients with AQP4-IgG-positive NMOSD and MOGAD16
Improvements in Quality of Life at 1 Year in Patients Treated with Cladribine Tablets for Highly Active Relapsing Multiple Sclerosis: An Interim Analysis of Clarify-MS16
Distinct patterns of MRI lesions in MOG antibody disease and AQP4 NMOSD: a systematic review and meta-analysis16
Stress indicators in minorities with multiple sclerosis16
The effects of balance training on cognitive function in persons with multiple sclerosis: A systematic review and meta-analysis16
Quantification of normal-appearing white matter damage in early relapse-onset multiple sclerosis through neurite orientation dispersion and density imaging16
Type of serum collection tube does not impact neurofilament light chain levels16
Epidemiology of multiple sclerosis in West bank of Palestine16
Targeting miR-223 enhances myeloid-derived suppressor cell suppressive activities in multiple sclerosis patients16
“It's on the tip of my tongue!” exploring confrontation naming difficulties in patients with multiple sclerosis16
Patients with multiple sclerosis: COVID-19 related disease activity and hospitalisations based on a nationwide cohort study16
A rare presentation of Susac syndrome: Report of three pediatric cases16
Moderate-to-vigorous physical activity is associated with processing speed, but not learning and memory, in cognitively impaired persons with multiple sclerosis16
Psychometric measurement properties and reference values of the six-spot step test, the six-minute walk test, the 25-foot walk test, and the 12-item multiple sclerosis walking scale in people with mul16
Clinical outcomes and prognostic factors in patients with optic neuritis related to NMOSD and MOGAD in distinct ethnic groups from Latin America16
Reliability of mobile video-oculography in multiple sclerosis patients using an iPad: A prospective validation study16
De-Escalation of Anti-CD20 Monoclonal Antibodies to Low-Moderate Efficacy Disease-Modifying Treatments in Patients with Relapse-Remitting Multiple Sclerosis: The Initial Iranian Experience15
Cross-Cultural Adaptation and Psychometric Evaluation of the Multiple Sclerosis Walking Scale-12 Arabic Version15
Persistence to the Oral Disease-Modifying Therapies for Multiple Sclerosis: A Population-Based Study in Iranian Patients15
Is Hepatitis C Virus Incriminated in Pathogenesis of Multiple Sclerosis?15
Seasonal Variation of Multiple Sclerosis Relapses in Oman15
Phase 3 REMODEL I/II Trials: Efficacy, Safety, and Tolerability of Remibrutinib in Patients with Relapsing Multiple Sclerosis15
A Case of Myasthenia Gravis Treated with Ocrelizumab15
An Unusual Presentation of Multiple Sclerosis as Acute Vestibular Syndrome: A Case Report15
Alexithymia in Multiple Sclerosis: Clinical and Radiological Correlations15
Personality Traits of Patients with Multiple Sclerosis and their Correlation with Anxiety and Depression Levels15
Real-Saudi Experience with Ocrelizumab in Relapsing Multiple Sclerosis15
Upbeat Nystagmus and Ataxia in a Case of Myelin Oligodendrocyte Glycoprotein (MOG)-IgG-Associated Disease15
Oral Status of Patients with MS in a Population of Western and Southwestern Algeria15
NMO Complicated by a PRES Syndrome as an Initial Manifestation15
A Novel Rabbit Model of EBV Infection to Understand the Role of the Virus in the Pathogenesis Multiple Sclerosis15
Multiple Sclerosis Patients Characteristics in Egypt15
Is Weight Loss a Presenting Symptom of Multiple Sclerosis15
Clinical Characteristics and Demographics of NMOSD/MOGAD from a Single Tertiary Center in Dubai, UAE14
Characteristics of Patients with Newly Diagnosed Multiple Sclerosis: A Five-Year Study at Benghazi Medical Center, Benghazi, Libya14
Is multiple sclerosis a glymphaticopathy?14
Efficacy and Safety of Rituximab in Moroccan Multiple Sclerosis Patients14
Can neurofilament lightchain as endpoint in Phase 2 derisk clinical disability worsening in Phase 3 in multiple sclerosis?14
Physical Activity in People with Multiple Sclerosis: Which Clinical Characteristics are Important?14
The Importance of Peripheral Vestibular Assessment in Diagnosing Imbalance in People with Multiple Sclerosis14
157. Remibrutinib Exposure in Cerebrospinal Fluid: Insights from a Study in Healthy Subjects14
Comparison of Time to Clinically Meaningful Improvement in Neuro-QOL in Patients Treated with Natalizumab Versus Ocrelizumab14
Time to Qualifying Relapse by Previous Disease-Modifying Therapy Status in Patients with Relapsing Multiple Sclerosis Treated with Cladribine Tablets Over 2 Years in the CLARIFY-MS Study14
EDSS and Infratentorial White Matter Lesion Volume are Considered Predictors of Fatigue Severity in RRMS14
Prevalence and incidence of multiple sclerosis in Isfahan, Iran between 1996 and 2021: A population-based study14
Medical Histories and Comorbidities Among Patients with Neuromyelitis Optica Spectrum Disorder, a Comprehensive Study from Iran14
Effects of 6-Month Treatment with Dimethyl Fumarate (DMF) on Treatment Satisfaction and Work Improvement in Patients with Relapsing Remitting Multiple Sclerosis (RRMS) (Interim Data Analysis)14
Safety and Efficacy of Evobrutinib and Tolebrutinib in Relapsing Multiple Sclerosis: A Meta-Analysis of Recent Randomized Control Trials14
Is There Any Benefit in Extended-Interval Dosing Regimen of Natalizumab for Patients with Relapsing-Remitting Multiple Sclerosis? Results from a Systematic Review and Meta-Analysis14
Influence of Cigarette, and Waterpipe Smoking, Alcohol, and Drug Consumption on the Occurrence of Late-Onset Multiple Sclerosis14
Clinical characteristics of pediatric and adult myelin oligodendrocyte antibody-associated disease (MOGAD): A single-center study in the Northeast14
181. The Real-world Efficacy and Safety of Off-label Rituximab in a Large Cohort of Middle Eastern Multiple Sclerosis Patients14
102. When Multiple Sclerosis and Neuro Behcet Disease Meet: What Management to Adopt?14
The Management of Lower Urinary Tract Symptoms in Multiple Sclerosis: an Umbrella Review14
Dilatation of the bridging cerebral veins in multiple sclerosis correlates with fatigue and suggests an increase in pressure14
Myelin-Oligodendrocyte Glycoprotein Antibody-Associated Disease and Intracranial Hypertension: A Case Report14
Geographic heterogeneity in the association of varicella-zoster virus seropositivity and multiple sclerosis: A systematic review and meta-analysis14
Impact of automatic tools for detecting new lesions on therapeutic strategies offered to patients with MS by neurologists14
Real-World Evidence with Five-Year Data (2017-2022) on the Use of Cladribine Tablets in Patients with Multiple Sclerosis in England: an Updated Analysis from the CLARENCE Study14
Real-World Efficacy and Safety Profile of Ocrelizumab in Adult Emirati Multiple Sclerosis Patients: A Retrospective Study from Cleaveland Clinic Abu Dhabi14
Cognitive rehabilitation and mindfulness reduce cognitive complaints in multiple sclerosis (REMIND-MS): A randomized controlled trial14
Disease Progression in Tunisian Pediatric Multiple Sclerosis14
Clinical and neuroimaging characteristics of MOG autoimmunity in children with acquired demyelinating syndromes14
Smoking, cardiovascular risk factors and LRP2 gene variation: Associations with disease severity, cognitive function and brain structure in primary progressive multiple sclerosis14
34. Evaluation of the Predictive Value of the Bands CSF Oligoclonals on the Prognosis in Terms of Disability and Risk of rRelapse in Patients Adults with MOGAD13
152. Efficacy of Frexalimab on Physical and Psychological Impacts and Fatigue in Relapsing Multiple Sclerosis: Findings from MSIS-29v2 and PROMIS-Fatigue-MS-8a Assessments in a Phase 2 Trial13
40. Assessment of Serum Zonulin as a Marker of Altered Intestinal Permeability in Patients with Multiple Sclerosis13
72. Prevalence, Characteristics and Risk Factors of Seizures Among Patients with Multiple Sclerosis13
57. Cognitive Decline and Motor Handicap in Multiple Sclerosis Patients13
125. Investigating Psychoses in Pediatric-Onset Multiple Sclerosis: A Systematic Review of Case Reports13
99. Pediatric Multiple Sclerosis Altered Diagnosis in a Tertiary Referral Center: A Retrospective Study13
Multiple sclerosis disease-modifying therapy use in the department of veteran affairs and Medicare: A comparative analysis13
88. Gender Issues in Multiple Sclerosis13
59. Patient Perspectives and Nursing Satisfaction in the Evaluation of High Efficacy Treatment in Multiple Sclerosis: A Cross-sectional Study13
39. The Neuroimmunological Manifestations of Covid-19 the Most Extensive Review of Published Case Reports13
92. Paroxysmal Dystonia Presenting as the First Sign of Multiple Sclerosis: A case report13
Interleukin-6 inhibitors for neuromyelitis optica spectrum disorder (NMOSD): A systematic review and meta-analysis13
64. Psychological and Sexual Health in MS Patients: Findings from an Algerian Cohort13
4. The Prevalence of Comorbidities Associated with Multiple Sclerosis in Saudi Arabia13
0.16195797920227